https://www.selleckchem.com/products/eft-508.html
7% and 14.9%), none of the patients who received primary prophylaxis developed FN. Moreover, a decrease in neutropenic events resulted in a significant decrease in the mean duration of neutropenia (2.50 days to 0.08 days, P 0.001), the risk of hospitalization (29.8% to 2.2%, P 0.001), and the mean total hospital care cost for all chemotherapy cycles (790.80 to 486.00 US dollars, P 0.001). The use of pegfilgrastim prophylaxis during adjuvant TC chemotherapy is associated with significant decreases in the incidence of neutr
Like
Comment
Share
